Answers are grounded in this paper and cite their sources.
Tackling cancer with effective therapies is a major challenge our society faces with significant costs and complexities of designing and validating treatments. In this article we show that representation learning based on real-world data can suggest indications for which a chosen mechanism of action is likely to be effective. We trained a machine learning model to rank histology-based malignant indications against expected biological relevance of anti-PD-1 treatment, leveraging reference indications and an embedding generating approach for features based on events in the patient's medical journey. We call our approach INSPIRE. When restricting the model to data before broad establishment of PD-1 inhibitors in the clinic, the method successfully prioritizes 70% of subsequent approvals. This indicates that INSPIRE could accelerate the process of selecting, testing and eventually treating patients with effective drugs, therefore reducing costs and improving care for patients.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: